MW-401
Generalized Anxiety Disorder (GAD)
Pre-clinicalLead optimization
Key Facts
Indication
Generalized Anxiety Disorder (GAD)
Phase
Pre-clinical
Status
Lead optimization
Company
About MindWalk Holdings
MindWalk Holdings is a clinical-stage biopharmaceutical company dedicated to addressing unmet needs in central nervous system (CNS) disorders. The company's strategy is built on a unique technology platform designed to modulate specific neural pathways with improved safety and efficacy profiles. Its lead programs are advancing in clinical trials for major depressive disorder and Alzheimer's disease. As a public entity, MindWalk aims to translate its scientific insights into transformative treatments for patients with debilitating neurological conditions.
View full company profileTherapeutic Areas
Other Generalized Anxiety Disorder (GAD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BHV-7000 (Kv7.2/3 opener) | Biohaven | Phase 2 |
| GRX-917 (Deuterated Etifoxine) | atai Life Sciences | Phase 1 |
| NPH-201 | Neuphoria Therapeutics | Pre-clinical |